FDA extends review process for Novartis drug by three months
https://healthell.blogspot.com/2020/06/fda-extends-review-process-for-novartis.html
FDA extends review process for Novartis drug by three months
The review process for a drug to treat patients with relapsing multiple sclerosis was extended by three months.
